Heart & Cardiovascular Tests

This hub is for anyone building a baseline, with family history or risk factors (diabetes, high blood pressure, kidney disease), or monitoring therapy to lower cardiovascular risk. Core labs include the Lipid PanelApoBLp(a) (largely genetic), Non-HDL-CA1c & fasting glucosehs-CRP (contextual inflammation), NT-proBNP/BNP (heart-failure monitoring), Creatinine/eGFR and uACR (cardio-renal risk), and TSH (metabolic contributors). Results help guide preventionrisk stratification, and follow-up with your clinician.


What It Tests

Cardiovascular lab testing supports prevention and monitoring:

  • Atherogenic risk: Lipid Panel (LDL-C/HDL-C/TG)ApoB (particle number), Non-HDL-C (all atherogenic cholesterol), Lp(a) (largely genetic; often one-time).

  • Cardiometabolic risk: A1cfasting glucose (± fasting insulin if ordered).

  • Inflammation context: hs-CRP (avoid during illness/injury).

  • Cardio-renal risk: Creatinine/eGFR and uACR to refine risk and track kidney–heart interplay.

  • Thyroid contribution: TSH (± FT4) when dyslipidemia, palpitations, or fatigue suggest endocrine influence.

  • Heart-failure monitoring: NT-proBNP/BNP—useful in known or suspected HF under clinician guidance; not a general screening test.


Key Tests

Test Also Called (Synonyms) What It Measures Typical Prep (fasting?) Specimen Turnaround Related Panels Use Type (Screening / Risk / Monitoring) Notes (guardrails & context)
Lipid Panel TC, LDL-CHDL-CTG Core cholesterol profile 8–12 h fastpreferred Blood ~1–2 d Heart Risk, Cardio-Renal Screening/Risk/Monitoring Foundation for ASCVD risk; repeat under similar conditions
ApoB Apolipoprotein B Atherogenic particle number Fasting preferred for comparability Blood ~1–2 d Advanced Risk Risk/Monitoring Complements LDL-C; aligns with particle burden
Non-HDL-C TC − HDL-C All atherogenic cholesterol Calculated from lipid panel Blood ~1–2 d Advanced Risk Risk/Monitoring Useful when TG elevated; treatment-goal friendly
Lipoprotein(a) Lp(a) Genetic lifetime risk factor No fasting Blood ~1–2 d Genetic Risk Risk Largely one-timebaseline; high values raise lifetime risk
A1c HbA1c ~3-month glycemia No fasting Blood ~1–2 d Metabolic Risk Screening/Monitoring Pair with glucose; some conditions limit accuracy
Fasting Glucose ± Insulin FPG; fasting insulin Glycemia/insulin resistance context 8–12 h fast Blood Same–1 d Metabolic Risk Screening/Monitoring Use trends; consider with A1c and lipids
hs-CRP High-sensitivity CRP Low-grade inflammation No fasting Blood ~1–2 d Advanced Risk Risk/Monitoring Do not test during acute illness/injury
Creatinine/eGFR Kidney filtration No fasting Blood Same–1 d Cardio-Renal Monitoring/Risk Track over time; interpret with uACR
uACR Urine albumin/creatinine ratio Early kidney damage First-morning urine preferred Urine ~1–2 d Cardio-Renal Risk/Monitoring Small increases matter, esp. with diabetes/HTN
TSH (± FT4) Thyroid panel Endocrine effects on lipids/HR No fasting Blood ~1–2 d Thyroid Check Screening/Monitoring Consider if dyslipidemia or palpitations
NT-proBNP / BNP natriuretic peptides Heart-failure status No fasting Blood ~1–2 d HF Monitoring Monitoring Use in suspected/known HF; not a general screen

When to Test

  • Baseline adult screening or annual wellness with risk factors.

  • Family history of premature ASCVD, very high LDL-C, or known Lp(a) elevation.

  • Monitoring after starting/adjusting therapy (statins, ezetimibe, PCSK9 inhibitors, GLP-1s, SGLT2 for diabetes/CKD).

  • Diabetes, hypertension, CKD, obesity, metabolic syndrome (cardio-renal/metabolic risk profiling).

  • Heart-failure management under clinician guidance (NT-proBNP/BNP).

  • Not for acute symptoms: chest pain or neurologic deficits → emergency care (not mail-order labs).


How to Prepare

  • Fasting: 8–12 hours for lipidsfasting glucose, and fasting insulin; water is fine.

  • Timing: Prefer morning draws; keep sleep/diet/activity consistent across repeats.

  • Activity: Avoid strenuous exercise 24–48 h before hs-CRP (and CK if ordered).

  • Medications & supplements: List statinsezetimibePCSK9GLP-1/SGLT2niacinfish oilthyroid medsdiuretics, and biotin (assay interference).

  • Hydration: Normal intake; extreme fluids can dilute urine for uACR.


Interpreting Results

  • ApoB / Non-HDL-C: Often better reflect atherogenic burden than LDL-C alone; targets are clinician-guided.

  • Lp(a)Genetic; usually one-time measurement. If high, manage overall risk more aggressively with your clinician.

  • A1c & glucose: Combine for fuller cardiometabolic context; some conditions limit A1c accuracy—use clinical judgment.

  • hs-CRP: Contextual marker of inflammation; avoid testing during illness, injury, or right after intense exertion.

  • Cardio-renal: Track eGFR uACR together—small changes over time matter, particularly with diabetes or hypertension.

  • NT-proBNP/BNP: Helpful in heart-failure diagnosis/monitoring; not a wellness screen.

  • Acute ischemia/embolismTroponin/D-dimer are acute-care tests—don’t self-order for screening.


Related Conditions

  • Atherosclerotic Cardiovascular Disease (ASCVD) Risk

  • Familial Hypercholesterolemia (FH)

  • Hypertension & Cardio-Renal Risk (CKD)

  • Diabetes / Metabolic Syndrome

  • Heart Failure

  • Thyroid-related Dyslipidemia


Bundles & Panels


FAQs

Do I need to fast for heart labs?
Yes for lipidsfasting glucose, and fasting insulin (8–12 hours). Most others don’t require fasting.

ApoB vs LDL-C—what’s the difference?
ApoB counts atherogenic particles; LDL-C measures cholesterol content. ApoB can better reflect risk in many people.

Is Lp(a) a one-time test?
Usually yes—it’s largely genetic. Re-test only if your clinician advises.

What does hs-CRP tell me?
It’s a contextual inflammation marker that can refine risk in some cases; don’t test when you’re ill or injured.

When should I recheck cholesterol after starting a statin?
Clinicians commonly recheck 4–12 weeks after a medication change, then periodically.

Should everyone get NT-proBNP?
No. It’s primarily for suspected/known heart failure, not routine screening.

Can supplements or biotin affect results?
High-dose biotin can interfere with some immunoassays; list all supplements and meds.

What labs reflect cardio-renal risk?
eGFR and uACR together provide early insight into kidney–heart risk.

Are advanced markers like Lp-PLA2 or homocysteine necessary?
They can be context-specific; many people are well-served by ApoB/Non-HDL-C plus standard lipids.

I have chest pain—should I order a troponin online?
No. Seek emergency care immediately. Troponin belongs in acute medical evaluation.


References

  • AHA/ACC — Cholesterol management & risk assessment guidance (ApoB, Non-HDL-C, Lp[a] context).

  • USPSTF — Recommendations for lipid screening.

  • ADA — Standards of Care in Diabetes for A1c/glucose.

  • KDIGO — CKD evaluation and use of eGFR/uACR for cardio-renal risk.

  • HFSA/ACC/AHA — Guidelines on NT-proBNP/BNP use in heart failure.

  • Endocrine Society — Thyroid testing in clinical practice.

Last reviewed: September 2025 by Ulta Lab Tests Medical Review Team

Other types of conditions may affect either the heart or the blood vessels. 

  • Congenital heart disease – malformation of the very structure of the heart occurring during development 
  • Valvular disease – defective valves (either congenital or acquired) 
  • Cardiomyopathy – weaker heart muscle 
  • Myocarditis – the inflammation of the myocardium (heart muscle) 
  • Vasculitis – the inflammation of blood vessels 
  • Thrombosis – blood clots occurring in the veins that can migrate to other parts of the body, causing embolism 
  • Atrial fibrillation – the irregular beating of the heart that can lead to severe medical complications such as blood clots, heart failure, and stroke

Heart disease is frequent and affects people of all ages and genders. As a result, it's critical to comprehend the risk factors and take preventative measures. Thankfully, you can understand your risk factors and make lifestyle adjustments to help avoid future heart problems by using blood tests to screen and monitor for cardiovascular conditions. 

Order your comprehensive cardiovascular diagnostic tests that are highly accurate and dependable, allowing you to make informed health decisions. To view the lab tests that can be used to diagnose and monitor your condition, click the link provided below.

To learn more about the conditions and lab tests that can be used to detect, diagnose and monitor cardiovascular disease, click the link below.

SEE BELOW THE LIST OF TESTS FOR MORE INFORMATION ABOUT Heart & Cardiovascular Tests

Browse Heart & Cardiovascular Tests Subcategories

Cardiovascular disease (CVD) is an umbrella term that includes a series of disorders that affect either the heart or the blood vessels. 

Cardiovascular disease is usually the reflection of chronic conditions that evolve over long periods of time. Nevertheless, cardiovascular disease may also trigger acute conditions such as strokes and heart attacks. These conditions occur unexpectedly when a blood vessel gets blocked and stops supplying the heart or the brain with blood. 

Most people use the term CVD to describe medical conditions that are associated with atherosclerosis, the thickening of arteries as a result of plaque build-up that prevents the blood from flowing freely through these vessels. 

Risk Factors 

Cardiovascular is more frequent among people who have hypertension, who have high blood cholesterol, who are overweight, who lead a sedentary life, who smoke, or who have diabetes. Therefore, public health services focus on keeping the CVD rate under control by recommending people to

  • Switch to a healthy diet 
  • Become more active by exercising regularly 
  • Avoid or quit smoking 
  • Keep their diabetes at bay by monitoring their blood sugar levels 

Unfortunately, some risk factors are impossible to control, including family history, gender, and age.  As the older one gets, the higher their risk of cardiovascular disease. 

Men have a higher risk of heart disease; however, women’s risk also increases to equal that of males after menopause. A family history of coronary heart disease or stroke before 55 years of age for a male first-degree relative or before 65 years of age for a female relative increases the risk. 

The American Heart Association and the American College of Cardiology developed a series of guidelines for CVD risk assessment. Their main goal was to come up with a more accurate and exhaustive definition of the major factors involved in assessing the CVD risk. They also aimed to provide ways to reduce this risk by treatment and by choosing a healthier lifestyle. For instance, they released a downloadable software tool to predict 10-year and lifetime CVD risk values. This tool is intended for individuals between 40 and 79 years of age. This model takes into consideration a range of factors such as age, gender, race, blood cholesterol levels, blood pressure, smoking habits, and the presence of diabetes. Some experts found this tool inaccurate, saying that it overestimated the risk, and therefore leading to more people treated with statins than necessary. Scientists who agreed with the tool found it a valuable resource, much better than any other risk calculator already available. The guidelines also stress the importance and the contribution of good doctor-patient communication concerning making the best treatment decisions for each patient. 

Types of CVD 

Here are some of the conditions that fall under the CVD umbrella: 

Coronary heart disease and coronary artery disease – they may lead to various conditions such as angina, heart attack, congestive failure, stroke, transient ischemic attacks, peripheral vascular disease, blood flow obstructions, aneurysms, and even gangrene. 

Other types of conditions may affect either the heart or the blood vessels. You can find more information on these conditions in our Heart Disease and Vasculitis articles. Here are a few of these diseases: 

  • Congenital heart disease – malformation of the very structure of the heart occurring during development 
  • Valvular disease – defective valves (either congenital or acquired) 
  • Cardiomyopathy – weaker heart muscle 
  • Myocarditis – the inflammation of the myocardium (heart muscle) 
  • Vasculitis – the inflammation of blood vessels 
  • Thrombosis – blood clots occurring in the veins that can migrate to other parts of the body, causing embolism 
  • Atrial fibrillation – the irregular beating of the heart that can lead to severe medical complications such as blood clots, heart failure, and stroke

The WHO estimates that CVD is responsible for 30% of all global deaths. Over 80% of these deaths occur in middle- and low-income countries, where people are more exposed to risk factors and have poor access to proper health care and preventative measures. Since CVD is the leading cause of death at a global level, it is a major concern of all governments and international medical organizations worldwide. Careful monitoring of individuals at risk can help to control the disease and decrease the number of deaths. 

Laboratory Tests:

 High-sensitivity C-reactiveCholesterol (with focus on LDL cholesterol), Triglycerides countLipid countAPOE Geno-typingLipoprotein ALp-PLA2FibrinogenHomocysteineApo A-IApo BMTHFR Mutation, Cardiac Risk Assessment